Preventive Healthcare Technologies, Products and Markets

According to a new technical market research report, PREVENTIVE HEALTHCARE TECHNOLOGIES, PRODUCTS, AND MARKETS (HLC070A) from BCC Research, the global market for new preventive healthcare technologies is valued at an estimated $11 billion in 2009, but is expected to increase to nearly $16.2 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 8.2%.

The largest segment of the market, products, is projected to reach $12.2 billion in 2014, after increasing at a CAGR of 7.4% from the 2009 value of $8.5 billion.

The services segment is estimated at $2.4 billion in 2009, and is expected to reach $4 billion in 2014, for a 5-year CAGR of 10.8%.

Preventive healthcare is likely to be an important component of any plan to restructure the U.S. healthcare system. At present, between 4% and 8% of the $2.4 trillion the U.S. spends annually on healthcare (i.e., $96 billion to $192 billion) goes for preventive care.

Broadly defined, preventive healthcare includes everything from over-the-counter (OTC) products designed to help users curb smoking or overeating to advanced genetic testing to identify a predisposition to certain cancers or other health problems. This report, however, focuses on a group of advanced preventive healthcare technologies and services.

Some of these technologies, such as certain vaccines, are decades old, while others (e.g., cytomics) are still largely at the experimental stage for clinical applications. This report generally focuses on new or emerging technologies, without being too rigid about what constitutes a “new” technology. Areas of particular interest include genomics, proteomics, cytomics, radiology, nanotechnology, informatics, and automation.

The report is intended especially for vendors of preventive healthcare-related products and services, as well as government agencies, healthcare policy analysts, and others seeking to understand the cost and preconditions for success of preventive healthcare initiatives.